Novo Nordisk PE Ratio 2006-2018 | NVO

Current and historical PE ratio for Novo Nordisk (NVO) from 2006 to 2018. The price to earnings or PE ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. The current PE ratio for Novo Nordisk (NVO) as of March 31, 2018 is 20.33.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $92.973B $16.962B
Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural resources.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $342.875B 16.39
Pfizer (PFE) United States $224.185B 13.80
Novartis AG (NVS) Switzerland $187.621B 16.09
Merck (MRK) United States $169.698B 15.17
AbbVie (ABBV) United States $149.801B 15.27
Sanofi (SNY) France $105.515B 13.36
GlaxoSmithKline (GSK) United Kingdom $101.582B 13.89
Eli Lilly (LLY) United States $97.721B 19.40
AstraZeneca (AZN) United Kingdom $94.553B 9.90
Bristol-Myers Squibb (BMY) United States $92.973B 18.29